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Abstract
Author Manuscript

The dramatic increase in the prevalence of antibiotic-resistant bacteria has necessitated a search
for new antibacterial agents against novel targets. Moiramide B is a natural product, broadspectrum antibiotic that inhibits the carboxyltransferase component of acetyl-CoA carboxylase,
which catalyzes the first committed step in fatty acid synthesis. Herein, we report the 2.6 Å
resolution crystal structure of moiramide B bound to carboxyltransferase. An unanticipated but
significant finding was that moiramide B bound as the enol/enolate. Crystallographic studies
demonstrate that the (4S)-methyl succinimide moiety interacts with the oxyanion holes of the
enzyme, supporting the notion that an anionic enolate is the active form of the antibacterial agent.
Structure–activity studies demonstrate that the unsaturated fatty acid tail of moiramide B is needed
only for entry into the bacterial cell. These results will allow the design of new antibacterial agents
against the bacterial form of carboxyltransferase.
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As the frequency of antibiotic-resistant infections steadily increases, there is an urgent need
for new antibacterial agents.1 Natural products or derivatives thereof constitute most of the
antibiotics that are in current use clinically. Natural product antibiotics inhibit only four
metabolic processes: DNA replication, transcription/translation, folate metabolism, and cell
wall biosynthesis.2 A critical pathway in assembly of the bacterial cell wall is fatty acid
synthesis. Thus, key enzymes in fatty acid biosynthesis can be considered targets for
antibacterial development.3–5 There are only four natural product antibiotics that inhibit
enzymes in fatty acid biosynthesis.1 One of those is moiramide B [compound 1 (Figure
1A)], which inhibits acetyl-CoA carboxylase and is the subject of this report.

Author Manuscript

The first committed and regulated step in fatty acid synthesis is catalyzed by acetyl-CoA
carboxylase (ACC).6 In most Gram-positive and Gram-negative bacteria, the enzyme
consists of three discrete proteins: biotin carboxylase, biotin carboxyl carrier protein, and
carboxyltransferase.7 These three proteins form a complex in vivo8 and catalyze the two-step
reaction shown in Scheme 1. Biotin carboxylase (BC) catalyzes the first half-reaction in
Scheme 1, which involves the ATP-dependent phosphorylation of bicarbonate to form a
reactive carboxyphosphate intermediate.9 The carboxyl group is then transferred to the
vitamin biotin, which in vivo, is covalently attached to the biotin carboxyl carrier protein
(BCCP). The second half-reaction is catalyzed by the carboxyltransferase (CT) component,
which transfers the carboxyl group from carboxybiotin to acetyl-CoA to make malonylCoA. When BC and CT are purified, they retain their activity, processing free biotin rather
than biotin attached to BCCP.10

Author Manuscript

Both the biotin carboxylase and the carboxyltransferase components of acetyl-CoA
carboxylase have been validated as targets for antibacterial agents. Three different synthetic
scaffolds have been reported to inhibit BC and exhibit antibacterial activity:
pyridopyrimidines,11 aminooxazoles,12 and benzimidazole-carboxamides.13 In contrast,
there is currently only one class of molecules known to inhibit CT, the natural products
moiramide B and andrimid. Moiramide B [compound 1 (Figure 1A)] is a pseudopeptide that
was extracted from a marine isolate of Pseudomonas fluorescens and was found to have
broad-spectrum antibacterial activity.14 Ten years after the discovery of the antibiotic
properties of moiramide B, Freiberg et al. determined that CT was the cellular target.15
However, the mechanistic basis for moiramide B inhibition of CT was unclear.
Herein, we report the three-dimensional structure of moiramide B bound to
carboxyltransferase. An interesting and important finding is that the enzyme binds the enol/
enolate of moiramide B (Figure 1B). Structure–activity studies of moiramide B are also
described, which dissect moiramide B into fragments, and the functions of those fragments
are determined with respect to the inhibition of CT and also the viability of Escherichia coli.
Comparison of the results is instructive vis-à-vis the roles of the various functionalities in
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moiramide B. The combined structure–function approach illustrates how nature has evolved
a tight binding inhibitor (Ki = 5 nM) of CT with antibacterial activity,15 invoking many
principles of medicinal chemistry. Our findings explain the molecular interactions between a
lead compound, moiramide B, and the enzyme active site, laying the foundation for future
design of antibacterial agents.

EXPERIMENTAL PROCEDURES

Author Manuscript

All chemicals and reagents were purchased from Sigma-Aldrich, Fisher, Acros,
NovaBiochem, and Fluka and used without further purification. Diisopropylethylamine and
triethylamine were dried and distilled from CaH2 and stored over KOH pellets. Dry
methanol was distilled from Mg turnings and stored over 3 Å molecular sieves. All reactions
were performed under a dry nitrogen atmosphere unless otherwise noted. Flash
chromatography was performed using 230–400 mesh silica gel (40–63 μm) from Fluka. Thin
layer chromatography was performed on aluminum-backed 60 F254 silica plates from EMD
Chemicals, Inc. Optical rotations were recorded on a Jasco P-2000 digital polarimeter. 1H
and 13C NMR spectra were recorded at room temperature on a Bruker AV-400 spectrometer.
All NMR experiments were performed in deuterated solvents, and the chemical shifts are
reported in standard δ notation as parts per million, using tetramethylsilane (TMS) and
CDCl3 as internal standards with coupling constants (J) reported in hertz. High-resolution
mass spectrometry (HRMS) was conducted using an Agilent 6210 electrospray ionization
time-of-flight (ESI-TOF) mass spectrometer.
(3S)-Methyl-pyrrolidine-2,5-dione (2)

Author Manuscript
Author Manuscript

A catalytic amount of 5% Pd/C [100 mg, 20% (w/w)] was added to a solution of (4S)methyl-N-O-benzyl-pyrrolidine-2,5-dione16 (500 mg, 2.28 mmol, 1.00 equiv) in dry
methanol (25 mL) and the mixture stirred under H2 for 1 h. The reaction mixture was
filtered through a pad of Celite, washed with methanol, and concentrated. The residue was
dissolved in acetonitrile (5 mL) and added dropwise to a stirred solution of 2bromoacetophenone (454 mg, 2.28 mmol, 1.00 equiv) in acetonitrile (5 mL) at room
temperature. A solution of triethylamine (477 μL, 346 mg, 3.42 mmol, 1.50 equiv) in
acetonitrile (2 mL) was added dropwise over 2 h, and the reaction mixture was stirred at
room temperature overnight. The mixture was concentrated and then partitioned between
CH2Cl2 (20 mL) and 5% hydrochloric acid (2 × 20 mL). The organic layer was washed with
brine (20 mL), dried over MgSO4, filtered, concentrated, and purified by flash
chromatography on silica gel eluting with a 5:1 CH2Cl2/EtOAc mixture to give 2 as a clear
oil (25 mg, 10%): Rf = 0.56 (4:1 EtOAc:CH2Cl2); [α]D20−16.3 (c 0.13, MeOH); 1H NMR
(CDCl3, 400 MHz) δ 1.37 (d, J = 7.2 Hz, 3H), 2.39 (dd, J = 16.1, 2.9 Hz, 1H), 2.81–3.07 (m,
2H), 8.22 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 16.5, 36.2, 37.6, 176.4, 180.7; HRMS
(ESI-TOF) calcd for C5H8NO2 (M + H)+ 114.0550, observed 114.0548.
(2E,4E)-N-[(S)-1-Phenylbutyl]hexa-2,4-dienamide (6)
Sorbic acid (50 mg, 0.45 mmol, 1.20 equiv) was added to a solution of (S)-1phenylbutylamine (55 mg, 0.37 mmol, 1.00 equiv) and TBTU (155 mg, 0.48 mmol, 1.30
equiv) in DMF (5 mL) followed by addition of N,N-diisopropylethylamine (162 μL, 120 mg,
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0.93 mmol, 2.50 equiv), and the mixture was stirred under N2 for 20 h. The solvent was
removed in vacuo, and the resulting residue was purified by flash chromatography on silica
gel eluting with a 1:1 Hex/EtOAc solvent to give 6 as a light yellow solid (66 mg, 73%): Rf
= 0.56 (1:1 Hex:EtOAc); [α]D24−136.2 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ
0.90 (t, J = 7.3 Hz, 3H), 1.18–1.42 (m, 2H), 1.70–1.87 (m, 5H), 5.05 (q, J = 7.7 Hz, 1H),
5.79 (d, J = 15.0 Hz, 1H), 5.95–6.23 (m, 3H), 7.10–7.38 (m, 6H); 13C NMR (CDCl3, 100
MHz) δ 14.5, 17.9, 19.5, 38.4, 52.5, 122.5, 125.9, 127.5, 127.7, 129.3, 130.5, 136.8, 140.6,
142.7, 165.7; HRMS (ESI-TOF) calcd for C16H22NO (M + H)+ 244.1696, observed
244.1704.
Enzyme Purification

Author Manuscript

Carboxyltransferase from Staphylococcus aureus was purified as previously described.17
Briefly, the genes encoding the α- and β-subunits of carboxyltransferase were placed in a
minioperon such that the N-terminus of the α-subunit contained a His tag. The genes were
overexpressed, and the protein was purified using nickel affinity chromatography followed
by gel-filtration chromatography.
Crystallization and Data Collection

Author Manuscript

Crystals were obtained by sitting drop vapor diffusion at 22 °C using a solution of 16
mg/mL carboxyltransferase and 0.5 mM moiramide B. The crystallization condition
contained a reservoir solution of 0.1 M MES (pH 5.0) and 1.6 M NH4SO4. The sitting drop
contained a well:protein volume ratio of 2:2 μL. Crystals appeared after 1–2 weeks and were
cryoprotected with a 20% (v/v) ethylene glycol/reservoir solution, and then that solution was
mixed with crystal mother liquor in a 1:1 ratio. The crystal was submerged in the
cryoprotectant and then immediately flash-cooled in liquid nitrogen. X-ray diffraction data
were collected to 2.6 Å at Advanced Photon Source beamline NE-CAT 24-ID-E equipped
with the ADSC Q315r detector. The images were processed using the XDS program suite18
and scaled using the Aimless program.19 Data collection and refinement statistics are listed
in Table 1.
Crystal Structure Determination

Author Manuscript

The molecular replacement procedure was applied to locate a solution using MOLREP.20 A
carboxyltransferase subunit of ACC from S. aureus (Protein Data Bank entry 2F9I) was used
as a search model. The positioned MR model was refined using the maximum likelihood
refinement in REFMAC20 with the TLS parameters generated by the TLSMD server.21 A
difference Fourier map unambiguously revealed the presence of the inhibitor between the αand β-chains (Figure 2a). The final model consists of residues 2–17 and 30–314 for the αchain, residues 29–241 and 247–283 for the β-chain, one Zn2+ cation, one inhibitor
molecule, three sulfate anions, one ethylene glycol molecule, and 21 water molecules.
Coot20 was used for model building throughout the refinement.
Kinetic Assays
Carboxyltransferase activity was measured in the reverse, nonphysiological direction and
was determined spectrophotometrically by measuring the production of acetyl-CoA using
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citrate synthase and malate dehydrogenase and following the reduction of NAD+ at 340
nm.22 Each reaction mixture contained 0.12 mg/mL malate dehydrogenase, 0.05 mg/mL
citrate synthase, 0.5 mM NAD+, 0.01 mM malic acid, 0.6 mg/mL bovine serum albumin
(BSA), and 100 mM Tris (pH 8.0). All reactions had constant malonyl-CoA and biocytin (a
biotin analogue) substrate concentrations of 150 μM and 6 mM, respectively. A final
concentration of 50 nM of compounds 1 and 3–7 was added to measure the effect on
activity. All reactions were conducted in a total of 0.5 mL in a 1 cm path length quartz
cuvette, and all reactions were initiated by the addition of enzyme and measured in triplicate.
Spectrophotometric data were collected using an Agilent Cary 60 UV–vis
spectrophotometer interfaced with a personal computer with a data acquisition program
supplied by Agilent.
Whole-Cell Growth Assays

Author Manuscript

A culture of E. coli strain JM109 was grown overnight in Luria-Bertani medium at 37 °C.
Culture tubes containing 2 mL of fresh medium were inoculated with 10 μL of the saturated
E. coli culture. Compounds 1 and 3–7 were dissolved in 100% DMSO to achieve a 5 mM
stock solution and inoculated into tubes to generate final concentrations of 50 μM. After
inoculation, the culture tubes were incubated for 4 h at 37 °C. Optical density (OD) readings
were measured at 600 nm in 1 mL plastic cuvettes. Spectrophotometric data were collected
using an Agilent Cary 60 UV–vis spectrophotometer.

RESULTS
Overall Structure of Moiramide B Bound to Carboxyltransferase

Author Manuscript

We previously described the synthesis of moiramide B on a milligram scale.16
Carboxyltransferase from S. aureus (SaCT) was cocrystallized with the synthetic moiramide
B. The structure of moiramide B bound to CT was determined and refined to a resolution of
2.6 Å. Data collection statistics and refinement details are listed in Table 1. A difference
Fourier map clearly established the presence of the moiramide B molecule in the active site
of CT, which is located at the interface of the α- and β-subunits of the heterotetramer
(Figure 2a).17 Binding in the active site is consistent with the observation that moiramide B
exhibits competitive inhibition with respect to the substrates.15

Author Manuscript

Pohlmann et al. identified four characteristic fragments of moiramide B: (1) the
pyrrolidinedione (succinimide) headgroup, (2) the L-valine-derived β-ketoamide, (3) βamino acid β-phenylalanine, and (4) the unsaturated fatty acid chain (Figure 1A).21 A key
observation from the structure of moiramide B bound to SaCT is that the α-carbon between
the ketone and amide is sp2-hybridized. It is not clear whether this is the enol tautomer of
the β-ketoamide or the enolate anion [compound 2 (Figure 1B and Figure S1)]. During
refinement, it became apparent that the fragment of moiramide B proximal to the sp2 carbon
(particularly the L-valine side chain) would not fit the density with moiramide B in the keto
form. In contrast, the enol/enolate of moiramide B readily fits the observed electron density.
It is worth noting that for andrimid (the homologue of moiramide B with two additional
carbons in the fatty acid chain), the pKa of the β-ketoamide has been determined to be 6.8 in
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60% methanol in water.23 Thus, enolate formation and stabilization in the active site of the
enzyme could be a facile process at physiological pH values.

Author Manuscript

The enolate of moiramide B is capable of hydrogen bonding interactions with CT that are
stronger than those of the neutral β-ketoamide (Figure 2b,c). Most of the carbonyl and
peptidic NH groups in moiramide B form one or more hydrogen bonds with residues from
both the α- and β-subunits of CT. This contradicts an earlier report that andrimid, and by
inference moiramide B, interacts solely with the β-subunit of CT.24 Each of the residues in
CT that hydrogen bond with moiramide B is conserved between Gram-negative and Grampositive bacteria, which is consistent with the broad-spectrum antibacterial activity of
moiramide B.14,15,25,26 Conserved residues in a protein suggest they are important for the
function of the protein. The observation that moiramide B interacts with conserved residues
also decreases the probability of a bacterium mutating one of these residues to become
resistant to moiramide B. A detailed analysis of the structural features for each of the
fragments of moiramide B (Figure 1A) follows.
Pyrrolidinedione Fragment

Author Manuscript

The crystal structure of moiramide B bound to carboxyltransferase reveals why the
pyrrolidinedione is such a good isosteric and isoelectronic surrogate for the enolate of biotin.
The partial double-bond character of the succinimidyl amides lends higher electron density
to the oxygen (cf., a cyclopentadione), providing for a stronger interaction in the oxyanion
hole. Sterically, the succinimide is a good fit, explaining why Pohlmann’s glutamide
analogues had little activity (vide infra).21 In CT, oxyanion holes are needed to stabilize the
enolates that form from each substrate during catalysis. In SaCT, the amide protons of
adjacent glycine residues, Gly199 and Gly200 in the α-subunit [Gly199(α) and Gly200(α),
respectively] and Gly207 and Gly208 in the β-subunit [Gly207(β) and Gly208(β),
respectively], serve as hydrogen bond donors, constituting the oxyanion holes that stabilize
the enolate and imidate anions in acetyl-CoA and biotin, respectively (Figure S2).17 It is
interesting to note that the C2(=O) group in the pyrrolidinedione headgroup (fragment 1,
numbering according to Needham et al.14) interacts directly with the amide hydrogen of
Gly208(β) (Figure 2c). The C5(=O) group interacts with the hydroxyl group of Ser198,
which is next to the oxyanion hole residue Gly199(α). On the basis of the orientation of
moiramide B in the active site of CT, the keto groups of the pyrrolidinedione headgroup
have allowed moiramide B to take advantage of the structural features of the enzyme,
resulting in a potent inhibitor of CT that is also bactericidal.

Author Manuscript

The crystal structure of moiramide B bound to the CT complex helps to explain the results
of previous structure–activity studies.26 Pohlmann et al. found that six-membered
piperidinedione (glutamide) analogues of moiramide B did not exhibit any antibacterial
activity. The imide carbonyls likely do not have the appropriate orientation to hydrogen bond
with the active site amino acids. Moreover, Pohlmann et al. found that an increase in the
bulk and hydrophobicity of substituents at the succinimide nitrogen resulted in a progressive
decrease in both the IC50 and MIC values,26 indicating that the size of this moiety had an
impact on enzyme inhibition and, thus, antibacterial activity.
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The crucial positioning of the pyrrolidinedione headgroup in the oxyanion holes is also
corroborated by a mutation in carboxyltransferase that provides resistance to andrimid.
Pantoea agglomerans, the bacterium that produces andrimid, is resistant to the antibacterial
properties of its metabolite, because of a mutation in the β-subunit (M203L and T206L in E.
coli and S. aureus carboxyltransferase, respectively).27 The Thr206 residue is adjacent to
one of the residues in the β-subunit (Gly207 and Gly208) that form the oxyanion hole.
Therefore, the T206L mutation could cause a local conformational change that weakens or
eliminates the binding of andrimid (and by inference moiramide B) to the enzyme.

Author Manuscript

The structure–activity relationships in Pohlmann et al. indicated that the (4S)-methyl group
on the pyrrolidinedione moiety was very important for antibacterial activity. Removal of the
methyl group, inclusion of two methyl groups at position 4, or replacement with an ethyl
group resulted in a total loss of activity.26,28 Thus, the methyl group contributes to the
potency of moiramide B as an inhibitor of CT. However, the crystal structure does not
provide an immediate explanation for this (e.g., nestling in a hydrophobic pocket of the
appropriate size).
Because moiramide B was synthetic in origin, we had intermediates that could be readily
accessed to probe the significance of the (4S)-methyl group, as well as the other structural
characteristics of moiramide B. Compounds that are representative of the fragments of
moiramide B (Figure 3) were tested for enzyme inhibition. Succinimide (3) is commercially
available, and (3S)-methyl succinimide (4) was synthesized from an intermediate precursor
during the synthesis of moiramide B (compound 1).16 Compounds 5 and 6 were also
intermediates generated during the synthesis of moiramide B (compound 1).16 Compound 7,
a stand-alone version of the “tail” fragment, was synthesized for this analysis.

Author Manuscript

The initial velocity of carboxyltransferase was measured in the presence of each of the
compounds at 50 nM, while the concentrations of substrates malonyl-CoA and biocytin were
held constant at a subsaturating level (Figure 4a and Table S1). Succinimide (compound 3)
was, within error, not an inhibitor of carboxyltransferase. However, addition of the (4S)methyl substituent (compound 4) resulted in a 50% decrease in CT activity compared to that
with the succinimide and an overall 65% decrease in activity when compared to the control.
Thus, the methyl group contributes significantly to the inhibition of carboxyltransferase by
moiramide B.

Author Manuscript

In the absence of structural evidence of the role of the methyl group, we propose three
possible functions. First, the weakly electron-donating methyl group may contribute to the
oxyanion character via an inductive effect, thereby strengthening the hydrogen bond
interactions with the active site amino acids. Second, the reduced energy for desolvation of
the methyl group (cf., a hydrogen) could increase binding affinity.29 Finally, the methyl
group likely exerts an influence on the conformation of the pyrrolidinedione ring, already
demonstrated to be key to effective binding. The observation that the methyl group in
compound 4 leads to significant inhibitory activity relative to compound 3 is consistent with
each of these hypotheses or some combination thereof (Figure 4a).
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There is a hydrophobic binding pocket for the side chain of the valine residue of moiramide
B. The pocket is composed of Met170(β) and Val235(β), as well as Ile221(α) and
Leu229(α) (Figure 5a). The binding pocket for the valine residue is not present in the
unliganded structure of SaCT.17 The pocket could form as a result of moiramide B binding,
or moiramide B binds to the conformation with the binding pocket that is in equilibrium
with the unliganded conformation. Nonetheless, formation of the pocket closes off the
binding site from the solvent (Figure 5b,c). An α-helix/loop motif in the β-subunit, which is
composed of residues Ala231–Asn241 (α-helix) and Glu242–Asp247 (loop), undergoes a
significant conformational change as a result of ligand binding (Figure 6). The loop segment
becomes disordered with no observable electron density in the liganded structure. The
largest movement (10.7 Å) is observed for the corresponding Cα atom of Asn241 of the
native and liganded structures.

Author Manuscript

In addition to the movement of the α-helix/loop motif, a short stretch (Ser165–Arg169) of a
β-sheet in the β-subunit moves slightly compared to the unliganded structure when
moiramide B is bound to SaCT. This conformational change allows for the formation of
hydrogen bonds between the carbonyl of Gly166 and both of the peptidic NH groups of
valine and β-phenylalanine fragments, as well as a hydrogen bond between the peptidic NH
group of Gly168 and the carbonyl oxygen of the L-valine β-ketoamide region (Figure 2c).

β-Phenylalanine Fragment

Author Manuscript

The comparison of CT inhibition by compounds 1 and 3–7 in Figure 4a indicates that while
the attachment of the L-valine group (compound 5) increased the level of CT inhibition only
slightly, the addition of the β-phenylalanine moiety (compound 6) increased the level of
inhibition an additional 15%. This suggests that the β-phenylalanine moiety is an important
component for increasing the binding affinity of moiramide B for the enzyme. As the
number of hydrogen bonds increases with the addition of each “backbone amide” (i.e., the
sequential addition of L-valine and β-phenylalanine residues), so does the binding affinity
(Figure 2c).

Author Manuscript

There is no defined hydrophobic binding pocket for the phenyl ring of the β-phenylalanine
residue. Indeed, there are no close interactions with any amino acids of the enzyme. Maybe,
like the methyl group on the pyrrolidinedone ring, the phenyl side chain has a desolvation
effect, leading to a higher affinity for carboxyltransferase. More importantly, this β-amino
acid presents a favorable spatial relationship between the amide NH group and the C=O
group to form hydrogen bonds with Gly166(β). Incorporation of an α-phenylalanine residue
might afford the desolvation effect, but the NH group would be in the wrong location to
engage in a productive hydrogen bond with Gly166(β). Moreover, we propose that in an αphenylalanine analogue, the phenyl group would provide steric interference for the oxyanion
hole in the α-subunit (residues 206–208), as well as residues 231–233 of the β-subunit loop
that moves in response to moiramide B binding.
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The unsaturated fatty acid tail interacts with Met134(β) and Leu229(β), and with
Met179(α). These interactions are not particularly strong as indicated by the higher B
factors for the atoms in the unsaturated fatty acid tail compared to the atoms of the other
fragments of moiramide B. Moreover, Figure 4a shows that there is little difference in CT
inhibitory activity between compounds 6 and 1, indicating little effect of the addition of the
fatty acyl tail. Compound 7 itself, embodying the fatty acyl tail and a phenylamide
functionality, exhibited no inhibition of CT, yet the bacterial cell expends considerable
metabolic energy incorporating this moiety into moiramide B.24

Author Manuscript

The role of the unsaturated fatty acid becomes readily apparent if the antibacterial activities
of compounds 1 and 3–7 are tested (Figure 4b). A final concentration of 50 μM for each
compound was added to culture media inoculated with E. coli and incubated for 4 h. With
the exception of moiramide B itself, none of the compounds exhibited any antibacterial
activity (Figure 4b, Figure S3, and Table S2). Even though compounds 4–6 all inhibited CT
significantly (Figure 4a), they did not display any antibacterial activity at a concentration of
50 μM (Figure 4B). The only difference between compound 6 and moiramide B (compound
1) is the incorporation of the fatty acyl tail. Therefore, it is tempting to suggest that the role
of the fatty acyl tail in the mechanism of action of moiramide B is transport of the molecule
into the bacterial cell.

DISCUSSION

Author Manuscript
Author Manuscript

Given the dominant role of natural products among clinically useful antibiotics, it is
instructive to determine in detail how the only natural product inhibitor of acetyl-CoA
carboxylase exerts its antibacterial effect. First, the observation that the bound form of the
drug appears to be the enolate is important. The fact that the drug binds in its enolate form
helps to explain the high affinity for the enzyme and by inference its potency as an
antibacterial agent. The enolate form of moiramide B is stabilized in the oxyanion hole of
carboxyltransferase, which is consistent with the fact that the enzyme must stabilize the
enolates that form in both substrates, acetyl-CoA and biotin, during catalysis. While this
finding has implications for understanding the catalytic mechanism of carboxyltransferase,
on a more practical level, it also provides direction for the design of future inhibitors of
carboxyltransferase. Second, the crystal structure reveals how nature expropriated the
oxyanion holes in carboxyltransferase to utilize a molecule with the appropriate structural
components to behave as a potent enzyme inhibitor. In nature’s version of structure-based
drug design, a methyl pyrrolidinedione functionality evolved to inhibit carboxyltransferase
by binding in the oxyanion holes found in both the α- and β-subunits. Third, in an example
of nature mimicking a common technique in medicinal chemistry, the addition of a methyl
group to the succinimide headgroup resulted in a significant increase in binding affinity.
Thus, the evolution of moiramide B utilized two common approaches used in anthropogenic
drug design. It will be interesting to see if these scaffolds can also be used in the design of
inhibitors of human acetyl-CoA carboxylase II, which has a mechanism similar to that of the
bacterial enzyme (i.e., it also utilizes two oxyanion holes for catalysis). The mitochondrial
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isoform (or acetyl-CoA carboxylase II) is involved in regulating fatty acid oxidation and is a
target for anti-obesity agents.30

Author Manuscript

While inhibition of the target enzyme is certainly important for an antibacterial agent, the
ability to gain entry into the bacterium is equally important. The studies here show that the
unsaturated fatty acid tail of moiramide B plays no role in inhibiting carboxyltransferase but
is critical for the molecule to enter the bacterial cell. Thus, it is instructional to see how
nature incorporated two distinct chemical moieties, a methyl pyrrolidinedione and an
unsaturated fatty acid, into a single molecule to solve two distinct biological problems,
enzyme inhibition and bacterial membrane transport. The lack of involvement of the
unsaturated tail in binding to CT points to the possibility of modifying moiramide B for
other applications. Conjugation of compound 6 with a fluorescent dye or moieties containing
nuclides for positron emission tomography can lead to the development of molecular
imaging agents for selectively detecting and imaging infectious diseases.31–33
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The presence of the unsaturated fatty acid tail, along with the phenyl and valine side chains,
makes moiramide B a very hydrophobic molecule. This is not characteristic of clinically
useful molecules that have broad-spectrum antibacterial activity, which tend to be more
polar.34 For example, broad-spectrum antibiotics typically have a logP (a measure of
hydrophobicity) of less than zero (i.e., hydrophilic), whereas the logP for moiramide B is
2.9. In fact, moiramide B has only one characteristic of broad-spectrum antibiotics, namely a
molecular weight of <600 Da (457.6 Da). The results described in this report provide a
blueprint from which to synthesize derivatives of moiramide B to increase solubility without
affecting (or maybe even increasing) potency and chemical stability. Lastly, the lessons
learned from analyzing how the natural process of evolution led to moiramide B will allow
for the development of new antibacterial agents against a novel target molecule, acetyl-CoA
carboxylase.
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Figure 1.
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Structure of moiramide B. (A) Moiramide B (compound 1) can be divided into four
fragments: (1) pyrrolidinedione headgroup, (2) L-valine-derived β-ketoamide, (3) β-amino
acid β-phenylalanine, and (4) unsaturated fatty acid chain. (B) Enolization between the C2
carbonyl of the pyrrolidinedione headgroup and the carbonyl of L-valine β-ketoamide
provides resonance around C3 of the pyrrolidinedione headgroup. The acidity of the αhydrogen of this diketone moiety allows for easy abstraction to generate an overall negative
charge that is stabilized between these select carbonyls (compound 2).
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Figure 2.
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Moiramide B binds at the subunit interface of carboxyltransferase. (a) Moiramide B binds at
the interface of the α-subunit (purple) and β-subunit (gold) of S. aureus carboxyltransferase,
which is shown as a surface rendering. Moiramide B is represented as green sticks. (b)
Stereoview of the moiramide B binding site of S. aureus carboxyltransferase. The Fo − Fc
electron density map is contoured at 2.5σ. The map was calculated before inclusion of
moiramide B atoms in the model. (c) Schematic diagram showing the interactions occurring
between moiramide B and active site residues. Dashes and numbers indicate hydrogen bonds
and distance in angstroms. Letters in parentheses indicate the subunit in which the residue is
located, A for the α-subunit and B for the β-subunit.
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Figure 3.
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Structures of the moiramide B intermediates. Succinimide (3), (3S)-methyl-2,5pyrrolidinedione (4), (3S)-L-valine-(4S)-methyl-2,5-pyrrolidinedione (5), (3S)-βphenylalanine-L-valine-(4S)-methyl-2,5-pyrrolidinedione (6), moiramide B (1), and the fatty
acyl tail fragment (7).
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Figure 4.
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Biological activity of the structural fragments of moiramide B. (a) Inhibitory activity of
compounds 1 and 3–7. Initial velocities of carboxyltransferase were measured in the
presence of each compound at 50 nM while the concentrations of the substrates, malonylCoA and biocytin, were held at subsaturating levels (150 μM and 6 mM, respectively).
Results were compared to the control (unless otherwise noted) using Student’s two-tailed t
tests (±standard deviations). ns means not significant. *p < 0.05; **p < 0.01; ***p < 0.001.
(b) Antibacterial activity of compounds 1 and 3–7. E. coli was inoculated with each
compound at a final concentration of 50 μM and incubated at 37 °C. After a 4 h incubation,
the absorbance at 600 nm was measured. Results were compared to the control using
Student’s two-tailed t tests (±standard deviations). ****p < 0.0001.
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Figure 5.
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Hydrophobic binding interactions of moiramide B. (a) Hydrophobic binding pocket for the
valine side chain of moiramide B (gray sticks). The residues that form the pocket include
Met170(β) and Val235(β) (gold) and Ile221(α) and Leu229(α) (purple). Distances are in
angstroms. (b) Binding cavity of moiramide B in S. aureus carboxyltransferase, which is
represented as a surface rendering. The α-subunit is colored purple and the β-subunit gold.
(c) Moiramide B ligand from the structure described in this report superimposed on
unliganded S. aureus carboxyltransferase (Protein Data Bank entry 2F9I). The color coding
is the same as in panel B.
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Figure 6.

Movement of the α-helix/loop motif in the β-subunit of carboxyltransferase after the binding
of moiramide B. The α-helix/loop motif in the unliganded enzyme is colored purple, while
the liganded form is colored yellow. Moiramide B is represented in ball and stick format,
and the protein is shown in surface representation with two residues from the β-subunit
noted (Phe230 and Gln249).
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Scheme 1.

Reactions of Biotin Carboxylase (BC) and Carboxyltransferase (CT) Along with the Sum of
the Entire Acetyl-CoA Carboxylase Reaction
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Data Collection and Refinement Statistics
Data Collection
wavelength (Å)

0.97918

resolution (Å)

40–2.6

temperature (K)

100

space group

C2

cell dimensions

a (Å)

153.807

b (Å)

49.445

c (Å)

100.048

β (deg)

91.94
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no. of complexes per asymmetric unit

1

no. of unique reflections

23238

Rpim

a,b (%)

6.1 (46.0)

Rsymc (%)

9.1 (68.7)

completeness (%)

99.1 (98.5)

redundancies

3.7 (3.7)

I/σ(I)

6.8 (1.5)

CC1/2d

0.995 (0.819)
Refinement
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resolution range (Å)

40–2.6

no. of reflections used in refinement

22099

σ cutoff used in refinement

0

R, Rfree(%)e

22.95, 27.59

no. of refined atoms
protein

4264

heterogeneous atoms

53

water

21

average B factor (Å2)
protein

66.9

moiramide

61.8

water

43.2

rmsd
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a

bonds (Å)

0.005

angles (deg)

1.005

Values in parentheses are for the highest-resolution shell.

b

, where ⟨Ihkl⟩ is the average of the symmetry (or

Friedel)-related observations of a unique reflection, Ii is the intensity of the ith observation, and ⟨Ii⟩ is the mean intensity of the reflection.

c

Rsym = Σ|Ii−⟨Ii⟩|/ΣIi, where Ii is the intensity of the ith observation and ⟨Ii⟩ is the mean intensity of the reflection.
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d

Reported in ref 19.

e

R = Σ‖Fo| − |Fc‖/Σ|Fo|, where Fo and Fc are the observed and calculated structure factors amplitudes, respectively. Rfree is calculated using 4.8%

of the reflections omitted from the refinement.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
Biochemistry. Author manuscript; available in PMC 2017 August 23.

